34
Participants
Start Date
May 14, 2013
Primary Completion Date
August 28, 2020
Study Completion Date
August 28, 2020
Everolimus
Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
Sandostatin LAR Depot
Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
New York University Medical Center SC-4, New York
Novartis Investigative Site, Bangkok
Clinical Research Alliance, Lake Success
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
H Lee Moffitt Cancer Center and Research Institute SC-2, Tampa
Novartis Investigative Site, Izmir
Central Indiana Cancer Centers SC, Indianapolis
Novartis Investigative Site, Arezzo
Mayo Clinic SC-2, Rochester
Washington University School of Medicine Dept of Oncology, St Louis
Nebraska Cancer Specialists Onc Dept, Omaha
Crescent City Research Consortium, LLC SC-3, Metairie
Hematology Oncology Services of Arkansas SC, Little Rock
Utah Cancer Specialists Utah Cancer (2), Salt Lake City
Oregon Health and Science University SC-8, Portland
Novartis Investigative Site, Leningrad Region
Rocky Mountain Cancer Centers SC, Greenwood Village
Stamford Hospital, Stamford
Novartis Investigative Site, Prague
Novartis Investigative Site, Groningen
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY